Sandip I. Patel - 20 Mar 2025 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Torsten Hombeck, as Attorney-in-Fact
Issuer symbol
AKTX
Transactions as of
20 Mar 2025
Net transactions value
$0
Form type
4
Filing time
24 Mar 2025, 17:00:12 UTC
Previous filing
22 Nov 2024
Next filing
29 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AKTX American Depositary Shares representing Ordinary Shares 451,857 20 Mar 2025 Direct F1
holding AKTX American Depositary Shares representing Ordinary Shares 6,250 20 Mar 2025 TT Insurance Investment LLC F1
holding AKTX American Depositary Shares representing Ordinary Shares 13,901 20 Mar 2025 Innovative Lifesci Investment LLC F1
holding AKTX American Depositary Shares representing Ordinary Shares 19,880 20 Mar 2025 Quest Bio LLC F1
holding AKTX American Depositary Shares representing Ordinary Shares 20,219 20 Mar 2025 Davis Island Ventures LLC F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKTX Stock Option (Right to Buy) Award $0 +175,000 $0.000000 175,000 20 Mar 2025 American Depositary Shares representing Ordinary Shares 175,000 $1.50 Direct F1, F2
transaction AKTX Stock Option (Right to Buy) Award $0 +225,000 $0.000000 225,000 20 Mar 2025 American Depositary Shares representing Ordinary Shares 225,000 $1.50 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.
F2 The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer.
F3 The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. Subject to the Reporting Person's continued service with the Issuer and shareholder approval covering the issuance of the ADS underlying this stock option, this option shall vest (i) 25% on the grant date (ii) 25% on December 31, 2025 and (iii) the remaining 50% shall vest ratably on a monthly basis over the 24 month period thereafter.